Extended Data Fig. 7: RA supports the proinflammatory state by inducing a monocyte recruitment phenotype.

a. Representative brightfield images at day 6 of culture (left), explant area quantifications over time (middle), and overall contraction quantifications (right) from fascia explants treated with RAR-selective agonists and pan-antagonist. N = 4 (area vs time) and 3 (total contraction) biological replicates. Two-tailed T-tests. Scale bars: 2 mm. b. Representative photos of control or RARγ agonist-treated wounds at 6 dpi (left), wound closure measurements (middle), and total wound contraction by 6 dpi (right). N = 6 wounds from 3 biological replicates. c. Flow cytometry strategy to identify treatment-induced changes in the recruitment of different immune cell types in wounds. d. Total cell type fractions at 3 (top) and 7 dpi (bottom) of general leukocytes (PTPRC⁺), monocytes/macrophages (ADGRE1⁺), neutrophiles (LY6G⁺), T (CD3⁺), and B lymphocytes (CD19⁺). N = 3 biological replicates. Two-tailed T-tests. e. Strategy for fascia fibroblast purification and culture (left). Expression changes (right) of proinflammatory (Ccl2 and Cxcl1) and myofibroblast markers (Acta2) in IL1β- (inflammation-inducing) or TGFβ1-containing media (myofibroblast-inducing). N = 3 technical replicates. Expression changes normalized to control medium. p values on bars from two-tailed T-tests (top) and 1-way ANOVA comparisons between treatments (bottom). f-g. Expression changes of indicated markers in inflammation- (f) and myofibroblast-inducing media (g) exposed to exogenous RA at indicated concentrations. N = 3 technical replicates. Expression changes normalized to control IL1β- (f) or TGFβ1-containing medium (g). p values on bars from two-tailed T-tests (top) and 1-way ANOVA comparisons between treatments (bottom).